Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eurofins Scientific SEERFSF -8.13%76 Equity-to-Asset is 0.41 as of Dec. 2025, which is 2% below its 10-year median of 0.42. GuruFocus rates ERFSF with a GF Score™ of 76/100 and a GF Value™ of $75.19 (Fairly Valued). The stock has 6 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, Eurofins Scientific SE ranks worse than 71.7% on this metric.
The historical rank and industry rank for Eurofins Scientific SE's Equity-to-Asset or its related term are showing as below:
ERFSF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36 Med: 0.42 Max: 0.5
Current: 0.41
During the past 13 years, the highest Equity to Asset Ratio of Eurofins Scientific SE was 0.50. The lowest was 0.36. And the median was 0.42.
ERFSF's Equity-to-Asset is ranked worse than 71.7% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59
vs ERFSF: 0.41
Eurofins Scientific SE (OTCPK:ERFSF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Eurofins Scientific SE Equity-to-Asset Related Terms
Eurofins Scientific SE Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Eurofins Scientific SE's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ERFSF vs TMO, DHR, IDXX: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, Eurofins Scientific SE's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins Scientific SE Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Eurofins Scientific SE's Equity-to-Asset falls into.
Eurofins Scientific SE Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Eurofins Scientific SE's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eurofins Scientific SE (ERFSF) has a Equity-to-Asset of 0.41 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Eurofins Scientific SE and its competitors. This is near median its historical median of 0.42. Over the past decade, Eurofins Scientific SE's Equity-to-Asset has ranged from 0.36 to 0.50. According to the industry distribution chart, Eurofins Scientific SE ranks #152 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 71.7%.
Is Eurofins Scientific SE's Equity-to-Asset too high?
Eurofins Scientific SE's current Equity-to-Asset of 0.41 is near median its 10-year median of 0.42. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 0.50. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.59. Eurofins Scientific SE's value of 0.41 is 30.5% below this industry median. Based on the distribution chart, Eurofins Scientific SE ranks #152 out of 212 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Eurofins Scientific SE has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's Equity-to-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Eurofins Scientific SE ranks #152 out of 212 companies for Equity-to-Asset. This places Eurofins Scientific SE in the lower half of its industry. The industry median Equity-to-Asset is 0.59. Eurofins Scientific SE's value of 0.41 is 30.5% below this benchmark. Historically, Eurofins Scientific SE's own Equity-to-Asset has ranged from 0.36 to 0.50 over the past decade. While the company's 10-year median is 0.42 vs. the industry median of 0.59, Eurofins Scientific SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.59, based on 212 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eurofins Scientific SE's current Equity-to-Asset of 0.41 is 30.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Eurofins Scientific SE and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eurofins Scientific SE's current Equity-to-Asset is 0.41, which is near median its own 10-year median of 0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (ERFSF) is currently considered Fairly Valued. The stock's GF Value™ is $75.19, compared to a current price of $74.02 — trading 1.6% below its estimated fair value. The current Equity-to-Asset is 0.41, which is near median its 10-year median of 0.42 and 30.5% below the Medical Diagnostics & Research industry median of 0.59. Eurofins Scientific SE's overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Eurofins Scientific SE (ERFSF), the current Equity-to-Asset is 0.41 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins Scientific SE (ERFSF) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be undervalued.
The current stock price of $74.02 is trading 1.6% below its estimated GF Value™ of $75.19.
GuruFocus considers Eurofins Scientific SE to be Fairly Valued.
Key valuation signals for ERFSF:
Equity-to-Asset: 0.41 (near median its 10-year median of 0.42)
GF Value™: $75.19 vs. price of $74.02 (1.6% below fair value)
Industry Position: 30.5% below the Medical Diagnostics & Research median (#152 of 212)
No single metric tells the full story. See the ERFSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 950 laboratories in 61 countries. Its revenue from Europe, North America, and the rest of the world contributes approximately 50%, 40%, and 10% of total revenue, respectively. Its areas of business activity are food, feed, and environmental testing ("life"), biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.
76GF Score
Get the complete analysis for ERFSF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERFSF has been successfully added to your 
